We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Physiological Status Unaffected by Blood Storage Duration

By LabMedica International staff writers
Posted on 07 Feb 2012
Alterations to both red blood cells (RBC) and their media during the storage process are potentially responsible for many of the adverse effects associated with RBC administration.

The impact of RBC storage duration has been evaluated on short-term pulmonary function and immunologic status in mechanically ventilated patients receiving RBC transfusion. More...


Scientists at the Mayo Clinic (Rochester, MN, USA) conducted a double-blind trial, where 50 patients were randomized to receive fresh RBC with a median storage duration of four days and 50 patients were randomized to receive standard issue RBC with a median storage duration of 26.5 days. All RBC units underwent prestorage leukoreduction. All the patients were mechanically ventilated in the intensive care unit (ICU).

The primary outcome measure of change was in pulmonary function arterial oxygen tension - fractional inspired oxygen (PaO2/FiO2) ratio. Other outcome measures included the immunologic status by estimating levels of tumor necrosis factor-alpha, interleukin-8, C-reactive protein and the coagulation status by measuring fibrinogen, anti-thrombin consumption. Measurements were obtained at baseline and within two hours of the completion of RBC transfusion.

No significant differences between groups were seen in the primary outcome measure of change in PaO2/FiO2 ratio: fresh RBC was 2.5 ± 49.3 and standard issue RBC was -9.0 ± 69.8. Similarly, no significant differences were seen for any of the other outcome measures of pulmonary function such as fraction of dead space ventilation, dynamic and static pulmonary compliance or the immunologic and coagulation status measurements.

Daryl J. Kor, MD, assistant professor of anesthesiology at the Mayo Clinic College of Medicine, said, "Our data do not support a significant effect of RBC storage duration on respiratory, immunologic or coagulation parameters in the immediate posttransfusion period. Previous observational studies linking RBC storage duration and respiratory complications may have suffered from bias and unmeasured confounding, which were more effectively addressed in our double-blind, randomized trial study design." The study was published online on January 26, 2012 in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Mayo Clinic




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.